Life sciences company shows strong performance after AIM float

Life sciences company shows strong performance after AIM float
The business raised £1.5m in a share placing earlier this year

LISTED life sciences business OptiBiotix has had a successful first year on AIM.

The business finished 2015 with a successful share placing, raising £1.5m to invest in a new product pipeline

The business reported £28.0m in revenues for the year to 30 November, but lacked in comparables.

The company did however say that it had made a loss of £1.42m, an increased loss on the year before, when losses reached £853,960.

The business raised £1.5m from the placing of 2m shares and has been investing heavily in its IP portfolio. OptiBiotix also signed four agreements with Nizo, Venture Life, CSL and an unspecified large US multinational

Stephen O’Hara, chief executive of OptiBiotix said: “I am delighted with the strong progress Optibiotix has made in our first full year trading on the AIM.

“In a short space of time we have built operational capability, progressed our development programmes, built on our IP portfolio, and signed multiple commercial agreements.

“Having validated our technology platforms during 2015 we are now extending their scope into new product and application areas to ensure a constant supply of new products entering the market and build the revenue streams of the future.”

 

Close